SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.08-2.9%Dec 26 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (14753)12/17/2004 5:02:08 PM
From: Arthur Radley  Read Replies (3) of 52153
 
Peter,
Concerning the funding issue, it is my understanding they don't plan an equity offering but rather the selling of a royalty interest in Trisenox. I have mixed feelings about this approach, but with the right partner I think this might be a good direction to move in shoring up their lack of funds. It will be interesting to see what Trisenox will bring in such a deal...hoping they can get a bundle and thus tip off how much this drug is expected to generate.

Any thoughts on the biplatinum compound they just got from the University of Vermont?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News